RNA Therapeutics Market Size, Share & Trends Analysis by Technology Type (mRNA, RNAi, ASO, Aptamers), Indication (Oncology, Infectious Diseases, Rare Genetic Disorders), Delivery Platform, End User, and Geography - Global Forecast to 2036

RNA Therapeutics Market Size, Share & Trends Analysis by Technology Type (mRNA, RNAi, ASO, Aptamers), Indication (Oncology, Infectious Diseases, Rare Genetic Disorders), Delivery Platform, End User, and Geography - Global Opportunity Analysis & Industry Forecast (2026-2036)

According to the research report titled, 'RNA Therapeutics Market Size, Share, and Trends Analysis by Technology Type (mRNA Therapeutics, RNA Interference [RNAi], Antisense Oligonucleotides [ASO], Aptamer-Based Therapeutics, Others), Indication (Oncology, Infectious Diseases, Rare Genetic Disorders, Cardiovascular Diseases, Neurological Disorders, Metabolic Disorders, Others), Delivery Platform (Lipid Nanoparticles [LNPs], Conjugate-Based Delivery [e.g., GalNAc], Viral Vector-Based Delivery, Polymer-Based Delivery Systems), End User (Hospitals and Clinics, Research Institutes and Academic Organizations, Pharmaceutical and Biotechnology Companies, Others), and Geography-Global Forecast to 2036,' the global RNA therapeutics market is projected to reach USD 40.98 billion by 2036 from USD 18.44 billion in 2026, growing at a CAGR of 8.3% during the forecast period (2026-2036). The growth of this market is primarily driven by the increasing prevalence of chronic and genetic diseases, coupled with the validated success of mRNA technology during the global pandemic. RNA-based candidates offer a unique ability to rapidly design and manufacture targeted therapies, making them ideal for personalized medicine and rapid response to emerging pathogens. Furthermore, significant venture capital and institutional investment in the biotechnology sector are accelerating the clinical pipeline and commercialization of next-generation nucleic acid medicines.

The global RNA therapeutics market is undergoing a profound structural transformation as the biopharmaceutical industry shifts from traditional small molecule and protein-based drugs toward information-based medicine. This evolution is being catalyzed by the ability to target the genetic drivers of disease at the transcript level, enabling the treatment of previously 'undruggable' targets. The industry is witnessing a significant transition from the initial success of mRNA vaccines toward broader therapeutic applications, including protein replacement therapies and RNA interference (RNAi) for chronic metabolic conditions. Furthermore, advancements in delivery platforms, such as lipid nanoparticles (LNPs) and GalNAc conjugates, are overcoming historical challenges related to RNA stability and tissue-specific targeting. This dynamic shift ensures sustained demand for flexible and scalable manufacturing infrastructure that can adapt to the rapid development cycles of personalized and precision RNA medicines.

Market Segmentation

The global RNA therapeutics market is segmented by technology type (mRNA therapeutics, RNA interference [RNAi], antisense oligonucleotides [ASO], aptamer-based therapeutics, and other RNA technologies), indication (oncology, infectious diseases, rare genetic disorders, cardiovascular diseases, neurological disorders, metabolic disorders, and other indications), delivery platform (lipid nanoparticles [LNPs], conjugate-based delivery, viral vector-based delivery, and polymer-based delivery systems), end user (hospitals and clinics, research institutes and academic organizations, and pharmaceutical and biotechnology companies), and geography. The study evaluation includes industry competitors and analyzes the market at the country level.

Based on Technology Type

By technology type, the mRNA therapeutics segment is expected to hold the largest share of the global RNA therapeutics market in 2026. This dominance is attributed to the widespread validation of mRNA platforms for infectious disease vaccines and the significant investment in expanding these platforms for therapeutic protein expression and cancer immunotherapy. Conversely, the RNA interference (RNAi) segment is projected to register the highest CAGR during the forecast period. This growth is fueled by the increasing approval of siRNA-based drugs for rare and chronic metabolic disorders, offering potent and long-lasting gene silencing effects that provide clear advantages over traditional therapeutic modalities.

Based on Indication

By indication, the infectious diseases segment is expected to hold the largest share of the global RNA therapeutics market in 2026. The massive global demand for mRNA-based vaccines and the ongoing development of candidates for diverse viral and bacterial pathogens drive this segment's leadership. Meanwhile, the oncology segment is projected to register the highest CAGR during the forecast period. This trend is driven by the accelerating clinical progress of personalized RNA cancer vaccines and targeted RNAi therapies designed to inhibit oncogenic drivers, as the industry moves toward more precise and individualized oncology care.

Based on Delivery Platform

By delivery platform, the lipid nanoparticles (LNPs) segment is expected to hold the largest share of the global RNA therapeutics market in 2026. LNPs have emerged as the gold standard for delivering mRNA, providing high encapsulation efficiency and protecting RNA molecules from degradation while facilitating cellular uptake. Conversely, the conjugate-based delivery segment, particularly GalNAc-siRNA conjugates, is projected to register the fastest growth during the forecast period. This growth is driven by the exceptional efficiency and safety of these systems for liver-targeted therapies, allowing for subcutaneous administration and extended dosing intervals in the treatment of various metabolic and genetic conditions.

Based on End User

By end user, the hospitals and clinics segment is expected to hold the largest share in 2026, reflecting the primary point of care for administering specialized RNA-based treatments and vaccines. Conversely, the pharmaceutical and biotechnology companies segment is projected to register the highest CAGR during the forecast period. This rapid growth is driven by the intensifying R&D efforts and the expansion of in-house RNA manufacturing capabilities as companies seek to secure their position in the rapidly evolving nucleic acid therapeutics landscape.

Geographic Analysis

In 2026, North America is expected to account for the largest share of the global RNA therapeutics market. The region's leadership is underpinned by a robust biotechnology ecosystem, high levels of R&D investment, and a favorable regulatory environment for orphan drugs and advanced therapies. The presence of industry pioneers such as Moderna, Alnylam, and Ionis in the United States further solidifies this dominance. Key companies in the North America market include Moderna, Inc. (U.S.), Alnylam Pharmaceuticals, Inc. (U.S.), Ionis Pharmaceuticals, Inc. (U.S.), Arrowhead Pharmaceuticals, Inc. (U.S.), and Sarepta Therapeutics, Inc. (U.S.).

Asia-Pacific is projected to witness the fastest growth during the forecast period. This expansion is primarily driven by increasing healthcare expenditure, a growing burden of chronic diseases, and the rapid expansion of biopharmaceutical manufacturing capabilities in China, India, and South Korea. Furthermore, government initiatives to promote precision medicine and the rising presence of local RNA-focused startups are significant catalysts. Key companies in the Asia-Pacific market include local research institutions and subsidiaries of global leaders like BioNTech and Moderna.

Europe remains a critical market for RNA therapeutics, characterized by a strong academic foundation in molecular biology and the presence of major developers such as BioNTech and CureVac in Germany. The region's focus on innovative cancer treatments and rare disease therapies drives the demand for RNA-based solutions. European regulatory frameworks are also evolving to provide clearer pathways for gene-based medicines. Key companies in the Europe market include BioNTech SE (Germany), CureVac N.V. (Germany), Silence Therapeutics plc (U.K.), and CRISPR Therapeutics AG (Switzerland).

Latin America is an emerging market for RNA therapeutics, driven by the increasing adoption of advanced medical technologies in Brazil and Mexico. The region is seeing a shift toward more personalized treatment options as healthcare providers seek to improve outcomes for oncology and rare disease patients.

The Middle East & Africa region is experiencing growing interest in RNA therapeutics as part of national efforts to strengthen healthcare infrastructure and develop local biotechnology hubs. Investments in genomic research and infectious disease prevention are expected to be major drivers of market growth in the region.

Key Players

The key players operating in the global RNA therapeutics market include Moderna, Inc. (U.S.), BioNTech SE (Germany), CureVac N.V. (Germany), Alnylam Pharmaceuticals, Inc. (U.S.), Ionis Pharmaceuticals, Inc. (U.S.), Arrowhead Pharmaceuticals, Inc. (U.S.), Regulus Therapeutics Inc. (U.S.), Arbutus Biopharma Corporation (U.S.), Translate Bio (Sanofi - France), Sarepta Therapeutics, Inc. (U.S.), Silence Therapeutics plc (U.K.), Dicerna Pharmaceuticals (Novo Nordisk - Denmark), Beam Therapeutics Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), and CRISPR Therapeutics AG (Switzerland).

Key Questions Answered in the Report-

• What is the value of revenue generated from the global RNA therapeutics market?
• At what rate is the RNA therapeutics demand projected to grow for the next 10 years?
• What are the historical market sizes and growth rates of the global RNA therapeutics market?
• What are the major factors impacting the growth of this market? What are the major opportunities for existing players and new entrants in the market?
• Which segments in terms of technology type, indication, delivery platform, and end user are expected to create major traction for the vendors in this market?
• What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the RNA therapeutics market?
• Who are the major players in the RNA therapeutics market? What are their specific offerings in this market?
• What are the recent strategic developments in the global RNA therapeutics market? What are the impacts of these strategic developments on the market?

Scope of the Report:

RNA Therapeutics Market Assessment -- by Technology Type

• mRNA Therapeutics
• RNA Interference (RNAi)
• Antisense Oligonucleotides (ASO)
• Aptamer-Based Therapeutics
• Other RNA Technologies

RNA Therapeutics Market Assessment -- by Indication

• Oncology
• Inexpensive Diseases
• Rare Genetic Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Metabolic Disorders
• Other Indications

RNA Therapeutics Market Assessment -- by Delivery Platform

• Lipid Nanoparticles (LNPs)
• Conjugate-Based Delivery (e.g., GalNAc)
• Viral Vector-Based Delivery
• Polymer-Based Delivery Systems
• Other Delivery Platforms

RNA Therapeutics Market Assessment -- by End User

• Hospitals and Clinics
• Research Institutes and Academic Organizations
• Pharmaceutical and Biotechnology Companies
• Other End Users

RNA Therapeutics Market Assessment -- by Geography

• North America (U.S., Canada)
• Europe (Germany, U.K., France, Italy, Spain, Switzerland, Sweden, Rest of Europe)
• Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore, Rest of Asia-Pacific)
• Latin America (Brazil, Mexico, Argentina, Chile, Colombia, Rest of Latin America)
• Middle East & Africa (UAE, Saudi Arabia, South Africa, Israel, Turkey, Rest of Middle East & Africa)